Agenus has secured up to $340 million in oversubscribed private financing to advance its Phase 3 ROBBIN trial evaluating the immunotherapy combination botensilimab (BOT) plus balstilimab (BAL) as neoadjuvant treatment for microsatellite-stable (MSS) colon cancer. The company is prioritizing this program based on encouraging Phase 2 data showing deep pathological responses and no reported disease recurrences to date, while discontinuing financial support for its separate late-stage metastatic colorectal cancer trial to focus resources on the earlier-stage opportunity.
The funding is expected to support the program through key clinical milestones and, if warrants are fully exercised, provide operational runway through 2031. The announcement highlights growing confidence in neoadjuvant immunotherapy for MSS colon cancer—a setting where few treatment advances have emerged in more than two decades—and underscores investor willingness to back late-stage oncology programs targeting high unmet clinical need.